DIPA’s core business is pharmaceuticals covering various therapeutic ranges. The products are licensed imports, branded generics and herbal products developed and manufactured by DIPA.

Over almost 50 years and with over 200 different products DIPA has developed a network of customers serving all kinds of medical professionals, such as haematologist, oncologist, cardiologist, nephrologist, internists, gynaecologist and neurologist.

DIPA had successfully launched as the first to market generic products in Indonesia: Rosuvastation and Valsartan in 2013, and Fexofenadine in 2014.


wp1c2337bc 05 06